FR054

CAS No. 35954-65-5

FR054( —— )

Catalog No. M28708 CAS No. 35954-65-5

FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
10MG 33 In Stock
25MG 53 In Stock
50MG 72 In Stock
100MG 111 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FR054
  • Note
    Research use only, not for human use.
  • Brief Description
    FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival.
  • Description
    FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival.(In Vivo):The effect of FR054 occurs through PGM3 inhibition instead of other off-target effects. FR054 (0.5-1 mM, 24-48 h) induces an early proliferation arrest followed by a marked cell death increase in breast cancer cells and induces apoptosis. FR054 (250 μM, 24 h) treatment efficiently affects both N- and O-glycosylation levels in MDA-MB-231 cells. FR054 induces endoplasmic reticulum stress and ROS-dependent apoptotic cell death .
  • In Vitro
    Cell Viability Assay Cell Line:MDA-MB-231 cells.Concentration:0.5-1?mM.Incubation Time:48 h.Result:Reduced viability and a significant increase of the apoptosis as compared to the control clone.
  • In Vivo
    Animal Model:Mice were subcutaneously injected with MDA-MB-231 cells.Dosage:1000?mg/kg.Administration:IP, single or fractionated dose (twice a day 500?mg/kg/dose).Result:Appears to have an in vivo antitumor efficacy that is higher when administered twice a day compared to single administration.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    35954-65-5
  • Formula Weight
    657.6
  • Molecular Formula
    C28H37N2O16
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (303.67 mM)
  • SMILES
    CC(OC[C@H]([C@H]1OC(C)=O)O[C@@H]2OC(C)=N[C@@H]2[C@H]1OC(C)=O)=OCC(OC[C@H]([C@H]1OC(C)=O)O[C@@H]2OC(C)=N[C@@H]2[C@H]1OC(C)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mukhopadhyay S., Chandalia S.B. Oxidative Chlorination, desulphonation, or decarboxylation to synthesize pharmaceutical intermediates: 2,6-Dichlorotoluene, 2,6-dichloroaniline, and 2,6-dichlorophenol. Org. Process Res. Dev. 1999;3:10–16.
molnova catalog
related products
  • Suc-Leu-Tyr-AMC

    Suc-Leu-Tyr-AMC is a fluorescent substrate for calpain I and II, papain (another cysteine protease), and is used to measure the chymotrypsin-like peptidase activity of the 20S proteasome (excitation max: 360 nm; emission max: 460 nm). Suc-Leu-Tyr-AMC can also be cleaved by the Ti protease from E. coli.

  • Soyasaponin II

    Soyasaponin II has antiviral effects, it can inhibit the replication of human cytomegalovirus, influenza virus, and human immunodeficiency virus type 1.

  • MSH Release Inhibiti...

    MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).